Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

被引：0
|
作者：
Xiang Zhang
Lotte C. A. Stiekema
Erik S. G. Stroes
Albert K. Groen
机构：
[1] Amsterdam University Medical Center,Department of Experimental Vascular Medicine
[2] University of Amsterdam,Human and Animal Physiology
[3] Wageningen University,Department of Vascular Medicine
[4] Amsterdam University Medical Center,undefined
[5] University of Amsterdam,undefined
来源：
Lipids in Health and Disease | / 19卷
关键词：
PCSK9 antibodies; Evolocumab; Lipoprotein(a); Metabolomics; VLDL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The onward march of PCSK9 inhibition
    Higgins, Catrin A.
    Rees, Alan
    CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (02) : 222 - 223
  • [42] Nine paths to PCSK9 inhibition
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 299 - U11
  • [43] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
    Katsiki, Niki
    Athyros, Vasilios G.
    Mikhailidis, Dimitri P.
    Mantzoros, Christos
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 74 : 43 - 46
  • [44] Nine paths to PCSK9 inhibition
    Asher Mullard
    Nature Reviews Drug Discovery, 2017, 16 : 299 - 301
  • [45] PCSK9-Hemmung – ein UpdateUpdate on PCSK9 inhibition
    Julius L. Katzmann
    Florian Custodis
    Stephan H. Schirmer
    Ulrich Laufs
    Herz, 2022, 47 : 196 - 203
  • [46] PCSK9 inhibition to combat hyperlipidaemia
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 366 - 366
  • [47] Inhibition of ApoCIII: the next PCSK9?
    Moens, Sophie J. Bernelot
    van Capelleveen, Julian C.
    Stroes, Erik S. G.
    CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (06) : 418 - 422
  • [48] PCSK9 is Elevated in HIV plus Patients
    Kohli, Payal
    Ganz, Peter
    Ma, Yifei
    Scherzer, Rebecca
    Deeks, Steven G.
    Maka, Kristinalisa
    Wasserman, Scott M.
    Scott, Rob
    Hsue, Priscilla
    CIRCULATION, 2014, 130
  • [49] EFFECTS OF PCSK9 VARIANTS AND PCSK9 LEVELS ON RISK OF ISCHEMIC STROKE
    Chen, W.
    Pan, Y.
    Wang, Y.
    Li, H.
    Meng, X.
    Wang, Y.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 629 - 629
  • [50] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects
    Wan, Hong
    Gumbiner, Barry
    Joh, Tenshang
    Riel, Tom
    Udata, Chandrasekhar
    Forgues, Philippe
    Garzone, Pamela D.
    CLINICAL THERAPEUTICS, 2017, 39 (11) : 2243 - 2259
12345